Literature DB >> 8970166

Tat-mediated protein delivery can facilitate MHC class I presentation of antigens.

P Moy1, Y Daikh, B Pepinsky, D Thomas, S Fawell, J Barsoum.   

Abstract

We have previously shown that the tat protein of HIV-1 can be used as a carrier to promote the intracellular delivery of heterologous proteins. Here we have tested if the tat-delivery technology can be used to direct MHC class I presentation of native protein, using ovalbumin (OVA) as a model system. We show that a tat-ovalbumin conjugate (tatOVA) can be delivered into cells and that subsequent processing and presentation occurs, resulting in effective and specific killing of these target cells by an OVA specific cytotoxic T-lymphocyte (CTL) line. Comparison with the E.G7 line that expresses the OVA gene indicates that tat-mediated delivery is as efficient as endogenous expression in this system. Tat-mediated antigenic protein delivery may be useful both as a research technique and, potentially, as a therapeutic or prophylactic vaccine.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8970166     DOI: 10.1007/BF02740767

Source DB:  PubMed          Journal:  Mol Biotechnol        ISSN: 1073-6085            Impact factor:   2.695


  36 in total

Review 1.  Cell biology of antigen presentation.

Authors:  J J Neefjes; F Momburg
Journal:  Curr Opin Immunol       Date:  1993-02       Impact factor: 7.486

2.  Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules.

Authors:  K L Rock; C Gramm; L Rothstein; K Clark; R Stein; L Dick; D Hwang; A L Goldberg
Journal:  Cell       Date:  1994-09-09       Impact factor: 41.582

Review 3.  Antigen presenting cells and mechanisms of antigen presentation.

Authors:  R W Chesnut; H M Grey
Journal:  Crit Rev Immunol       Date:  1985       Impact factor: 2.214

4.  Brefeldin A specifically inhibits presentation of protein antigens to cytotoxic T lymphocytes.

Authors:  J W Yewdell; J R Bennink
Journal:  Science       Date:  1989-06-02       Impact factor: 47.728

5.  Recognition of viral antigens by human influenza A virus-specific T lymphocyte clones.

Authors:  B Fleischer; H Becht; R Rott
Journal:  J Immunol       Date:  1985-10       Impact factor: 5.422

6.  Saponin adjuvant enhancement of antigen-specific immune responses to an experimental HIV-1 vaccine.

Authors:  J Y Wu; B H Gardner; C I Murphy; J R Seals; C R Kensil; J Recchia; G A Beltz; G W Newman; M J Newman
Journal:  J Immunol       Date:  1992-03-01       Impact factor: 5.422

7.  Saponin adjuvant induction of ovalbumin-specific CD8+ cytotoxic T lymphocyte responses.

Authors:  M J Newman; J Y Wu; B H Gardner; K J Munroe; D Leombruno; J Recchia; C R Kensil; R T Coughlin
Journal:  J Immunol       Date:  1992-04-15       Impact factor: 5.422

8.  Nonrandom catabolism of proteins in the formation of antigenic peptide fragments.

Authors:  D W Thomas; J L Schauster; M D Hoffman; G D Wilner
Journal:  J Immunol       Date:  1985-08       Impact factor: 5.422

9.  Proteolytic processing of ovalbumin and beta-galactosidase by the proteasome to a yield antigenic peptides.

Authors:  L R Dick; C Aldrich; S C Jameson; C R Moomaw; B C Pramanik; C K Doyle; G N DeMartino; M J Bevan; J M Forman; C A Slaughter
Journal:  J Immunol       Date:  1994-04-15       Impact factor: 5.422

10.  Induction of ovalbumin-specific cytotoxic T cells by in vivo peptide immunization.

Authors:  F R Carbone; M J Bevan
Journal:  J Exp Med       Date:  1989-03-01       Impact factor: 14.307

View more
  6 in total

1.  A replication-competent adenovirus-human immunodeficiency virus (Ad-HIV) tat and Ad-HIV env priming/Tat and envelope protein boosting regimen elicits enhanced protective efficacy against simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques.

Authors:  Thorsten Demberg; Ruth H Florese; Megan J Heath; Kay Larsen; Irene Kalisz; V S Kalyanaraman; Eun Mi Lee; Ranajit Pal; David Venzon; Richard Grant; L Jean Patterson; Birgit Korioth-Schmitz; Adam Buzby; Dilani Dombagoda; David C Montefiori; Norman L Letvin; Aurelio Cafaro; Barbara Ensoli; Marjorie Robert-Guroff
Journal:  J Virol       Date:  2007-01-17       Impact factor: 5.103

2.  Tat-Mediated Peptide Intervention in Analgesia and Anesthesia.

Authors:  Feng Tao; Roger A Johns
Journal:  Drug Dev Res       Date:  2010-04-01       Impact factor: 4.360

Review 3.  Replicating adenovirus vector prime/protein boost strategies for HIV vaccine development.

Authors:  L Jean Patterson; Marjorie Robert-Guroff
Journal:  Expert Opin Biol Ther       Date:  2008-09       Impact factor: 4.388

4.  A Tat subunit vaccine confers protective immunity against the immune-modulating activity of the human immunodeficiency virus type-1 Tat protein in mice.

Authors:  S M Agwale; M T Shata; M S Reitz; V S Kalyanaraman; R C Gallo; M Popovic; D M Hone
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-02       Impact factor: 11.205

5.  Selective enhancement of the uptake and bioactivity of a TAT-conjugated peptide inhibitor of glycogen synthase kinase-3.

Authors:  Aziza P Manceur; Brandon D Driscoll; Wei Sun; Julie Audet
Journal:  Mol Ther       Date:  2008-12-23       Impact factor: 11.454

6.  The targeted transduction of MMP-overexpressing tumor cells by ACPP-HPMA copolymer-coated adenovirus conjugates.

Authors:  Shuhua Li; Juanzhi Chen; Huiyong Xu; Jie Long; Xiaobin Xie; Yajie Zhang
Journal:  PLoS One       Date:  2014-07-07       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.